IA
LCTX icon

IndexIQ Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

IndexIQ Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-781,328
Closed -$715K – 640
2018
Q4 		$715K Sell
781,328
-184,589
-19% -$283K 0.02% 451
2018
Q3 		$1.98M Buy
965,917
+36,482
+4% +$76.6K 0.06% 343
2018
Q2 		$1.67M Sell
929,435
-7,290
-0.8% -$14.7K 0.05% 416
2018
Q1 		$2.17M Buy
936,725
+470,027
+101% +$1.1M 0.07% 184
2017
Q4 		$878K Buy
466,698
+179,546
+63% +$392K 0.03% 418
2017
Q3 		$713K Buy
287,152
+130,305
+83% +$323K 0.03% 392
2017
Q2 		$431K Buy
+156,847
New +$438K 0.02% 387

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

IndexIQ Advisors's LCTX Position: Q1 2019 in Review

IndexIQ Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q1 2019, closing a stake of 781,328 shares — an estimated $715K sold.

IndexIQ Advisors first reported a position in LCTX in Q2 2017 and held it in 7 quarters. The position peaked at $2.17M in Q1 2018. 118 funds tracked by Wall St. Rank hold LCTX as of Q1 2019.

  • IndexIQ Advisors reported no remaining Lineage Cell Therapeutics position as of Q1 2019 after selling out during the quarter.
  • IndexIQ Advisors sold 781,328 Lineage Cell Therapeutics shares in Q1 2019, an estimated $715K.
  • IndexIQ Advisors first reported a position in Lineage Cell Therapeutics in Q2 2017 and held it in 7 quarters.
  • IndexIQ Advisors's Lineage Cell Therapeutics position peaked at $2.17M in Q1 2018.
  • 118 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2019.

Based on IndexIQ Advisors's 13F filing for Q1 2019, filed 6 May 2019.